MedPath

Using Nicotine to Reverse Age-related Auditory Processing Deficits

Not Applicable
Recruiting
Conditions
Auditory Perceptual Impairment
Aging
Interventions
Other: Placebo gum
Other: Nicotine gum
Registration Number
NCT04971954
Lead Sponsor
University of California, Irvine
Brief Summary

The present study will evaluate the effects of both aging and nicotine on psychophysical tasks and electrophysiological measures. Nicotine will be administered to study participants in the form of gum that is available as an over-the-counter medication. The hypothesis is that nicotine will reverse the detrimental effects of aging on auditory processing. The proposed experiments will characterize the effects of nicotine and may eventually lead to improved treatments of hearing loss in a variety of patient populations and in healthy aging.

Detailed Description

Study participants will be recruited in two age groups: young (18-28 years) and old (60-85). Each participant will participate in two psychophysical and electrophysiological test sessions. For each of the two sessions, the participant will be administered gum before the test. For one of these sessions, the gum will be polacrilex that contains 6-mg nicotine, and for the other session, the gum will be a placebo control. The study will be double-blind, meaning that neither the experimenter nor the participant will know whether the participant has received nicotine or placebo for a given session. The study has a cross-over design, meaning that all participants will receive both nicotine and placebo in separate sessions. Finally, the order of drug administration will be counterbalanced, meaning that equal numbers of participants will receive 1) nicotine in session one and placebo in session two, and 2) placebo in session one and nicotine in session two.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
48
Inclusion Criteria
  • between 18 and 85 years of age
  • non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking dependency
  • cognitive performance within two standard deviations of the CERAD mean
Exclusion Criteria
  • less than 18 or greater than 85 years of age
  • deafness or excessive hearing loss
  • smokers with a score between 3 and 10 on the Fagerström index of smoking dependency
  • history of psychiatric illness, neurological disorders, diabetes mellitus, renal failure, or cardiovascular disease
  • regular use of prescription medications (excluding oral contraceptives)
  • drug dependency

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Placebo gumPlacebo gumThe placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
Nicotine gumNicotine gumNicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
Primary Outcome Measures
NameTimeMethod
Hearing thresholds1 hour

Hearing thresholds in dB SPL will be measured as a function of sound frequency from 125 Hz to 8000 Hz in quiet or in noise.

Envelope following responses2 hours

Electrophysiological responses will be recorded in response to amplitude or frequency-modulated sounds. The sounds will be presented at 70 dB SPL or a comfortable level. The EEG signal strength that is in synchrony with the modulation frequency in micro-Volts will be recorded.

Modulation detection1 hour

Amplitude-modulated sounds will be presented at 70 dB SPL or a comfortable level. The detection threshold in percent modulation depth (m= 0 to 100) will be recorded and converted into signal-to-noise ratios in dB (=20log(m)).

Secondary Outcome Measures
NameTimeMethod
Heart rate10 minutes

Pulse rate in pulses per minute will be measured via pulse oximetry.

Nicotine side effects10 minutes

Side effects will be rated on a 5-point scale including: 1 = none (no symptoms at all); 2 = mild (slight jitters); 3 = moderate (jittery, slight dull headache); 4 = moderately severe (jittery, dull headache, mild nausea); 5 = severe (jittery, dull or pounding headache, nausea, vomiting).

Mood change10 minutes

Mood change will be measured by a 9-category rating scale including: energy, contentedness, focus, relaxation, calmness, alertness, hunger etc.

Trial Locations

Locations (1)

Hearing and Speech Lab

🇺🇸

Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath